When Should the Seminal Vesicles be Included in the Target Volume in Prostate Radiotherapy?

Clinical Oncology

Volumn 19, Issue 5, 2007, Pages 302-307

  Bayman, N A ^a   Wylie, J P ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Prostate cancer; prostate specific antigen; radiotherapy; seminal vesicles; target volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDLINE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RECTUM HEMORRHAGE; SEMINAL VESICLE;

BIOPSY; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTUM; RISK; SEMINAL VESICLES;

EID: 34248523293     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.03.005     Document Type: Article

References (35)

1. Epstein J.I., Carmichael M., and Walsh P.C. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 149 (1993) 1040-1045
2. Guillonneau B., Debras B., Veillon B., et al. Indications for preoperative seminal vesicle biopsies in staging of clinically localized prostatic cancer. Eur Urol 32 (1997) 160-165
3. Eggener S.E., Roehl K.A., Smith N.D., et al. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol 173 (2005) 1150-1155
4. Katcher J., Kupelian P.A., Zippe C., et al. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 37 (1997) 871-876
5. Sandler H.M., McLaughlin P.W., Ten Haken R.K., et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 33 (1995) 797-801
6. Lee C.T., Dong L., Ahamad A.W., et al. Comparison of treatment volumes and techniques in prostate cancer radiation therapy. Am J Clin Oncol 28 (2005) 618-625
7. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
8. D'Amico A.V., Whittington R., Kaplan I., et al. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys 39 (1997) 335-340
9. Pisansky T.M., Zincke H., Suman V.J., et al. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys 34 (1996) 33-39
10. Zlotta A.R., Roumeguere T., Ravery V., et al. Is seminal vesicle ablation mandatory for all patients undergoing radical prostatectomy? A multivariate analysis on 1283 patients. Eur Urol 46 (2004) 42-49
11. Kestin L., Goldstein N., Vicini F., et al. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?. Int J Radiat Oncol Biol Phys 54 (2002) 686-697
12. Roach III M. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 1923-1924
13. Diaz A., Roach III M., Marquez C., et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30 (1994) 323-329
14. Guzzo T.J., Vira M., Wang Y., et al. Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol 175 (2006) 518-521
15. Ozgur A., Onol F.F., and Turkeri L.N. Important preoperative prognostic factors for extracapsular extension, seminal vesicle invasion and lymph node involvement in cases with radical retropubic prostatectomy. Int Urol Nephrol 36 (2004) 369-373
16. Salomon L., Porcher R., Anastasiadis A.G., et al. Introducing a prognostic score for pretherapeutic assessment of seminal vesicle invasion in patients with clinically localized prostate cancer. Radiother Oncol 67 (2003) 313-319
17. Lieberfarb M.E., Schultz D., Whittington R., et al. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys 53 (2002) 898-903
18. Koh H., Kattan M.W., Scardino P.T., et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 170 (2003) 1203-1208
19. Nguyen P.L., Whittington R., Koo S., et al. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 400-405
20. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol 14 (1996) 1770-1777
21. May F., Treumann T., Dettmar P., et al. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 87 (2001) 66-69
22. Wang L., Hricak H., Kattan M.W., et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238 (2006) 597-603
23. Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 78 Special No. 2 (2005) S103-S111
24. San Francisco I.F., Olumi A.F., Yoon J.H., et al. Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy. BJU Int 92 (2003) 924-928
25. Han K.R., Seligson D.B., Liu X., et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 171 (2004) 1117-1121
26. Hille A., Tows N., and Hess C.F. A comparison of three-field and four-field techniques in different clinical target volumes in prostate cancer irradiation using dose volume histograms: a prospective three-dimensional analysis. Br J Radiol 79 (2006) 148-157
27. Villers A.A., McNeal J.E., Redwine E.A., et al. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol 143 (1990) 1183-1187
28. Korman H.J., Civantos F., Block N.L., and Soloway M.S. Radical prostatectomy: is complete resection of the seminal vesicles really necessary?. J Urol 156 (1996) 1081-1083
29. Davis B.J., Wilson T.M., Slezak J.M., and Pisansky T.M. Histopathologic characterization of seminal vesicle invasion in prostate cancer: implications for radiotherapeutic management. Int J Radiat Oncol Biol Phys 51 (2001) 140-141
30. Epstein J.I., Partin A.W., Potter S.R., et al. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology 56 (2000) 283-288
31. Parker C., Haycocks T., Bayley A., et al. A dose-volume histogram analysis of the seminal vesicles in men treated with conformal radiotherapy to 'prostate alone'. Clin Oncol (R Coll Radiol) 14 (2002) 298-302
32. Khoo V.S. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 17 (2005) 560-571
33. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 241-249
34. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
35. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881